CytomX Therapeutics will report full-year 2025 results on March 16, 2026, before U.S. market open, followed by a webcasted...

TScan Therapeutics plans to initiate its first Phase 3 trial in the second quarter of 2026 for TSC-101 to...

Kamada will report fourth-quarter and full-year 2025 results on March 11, 2026, and host an investor call that morning....

EyePoint, Inc. reported year-end 2025 results and advanced its lead asset Duravyu, a bioerodible intravitreal insert of the TKI...

AnaptysBio will separate its business into two public companies in the second quarter of 2026, potentially as early as...

Dyadic Applied Biosolutions and Denmark’s Inzymes plan to commercialize a recombinant, non-animal bovine chymosin for cheese production in 2026,...

uniQure reported full-year 2025 results and a pivotal regulatory update: after a Type A meeting in January, FDA advised...

Zymeworks has set a clear 2026 inflection point: its partner plans to submit a supplemental BLA for Ziihera (zanidatamab-hrii)...

Belite Bio reported positive topline results from its pivotal Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt...

Bavarian Nordic’s board has begun a CEO succession process as Paul Chaplin prepares to step down for personal reasons,...